drug_type
RELEVANT_DRUG
intervention_type
Biologic (bispecific monoclonal antibody; targeted immunotherapy)
drug_description
IV bispecific IgG1 monoclonal antibody targeting EGFR and MET; blocks ligand-driven activation, inhibits PI3K/AKT/mTOR and RAS/RAF/MEK/ERK signaling, promotes receptor internalization/degradation, and induces ADCC/ADCP via Fc engagement; studied in EGFR-amplified glioblastoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Amivantamab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific IgG1 monoclonal antibody that binds EGFR and MET extracellular domains to block ligand-driven activation, inhibit downstream PI3K/AKT/mTOR and RAS/RAF/MEK/ERK signaling, promote receptor internalization and degradation, and engage Fcγ receptors to induce ADCC/ADCP by NK cells and macrophages.
drug_name
Amivantamab (JNJ-61186372)
nct_id_drug_ref
NCT06632236